Tuesday, September 22, 2020 7:00PM – 9:00 PM ET
This virtual program is at 7:00PM Eastern, 6:00PM Central, 5:00PM Mountain, and 4:00PM Pacific.
Click here to REGISTER
Access the clinical/provider tool kit, poster portal, and additional resources @ http://oncologynurse-ce.com
PROGRAM FEATURES
Online Personalized Poster Portal
Interactive, case-based learning environment
PRESENTATION TRACKS
HER2-Positive Breast Cancer
The Roles of Oncology Nurses in Next-generation Approaches to the Management of Advances HER2-Positive Breast Cancer
Andrea Rodriguez, CRNP, AOCNP Women’s Cancer Center Magee-Women’s Hospital University of Pittsburgh Medical Center Pittsburgh, PA
Triple Negative Breast Cancer (TNBC)
Optimizing Treatment with Immune Checkpoint Inhibitors: The Collaborative Care of Patients with Triple Negative Breast Cancer
Sramila Aithal, MD Director and Lead, Breast Center of Advanced Oncology Medical Oncologist and Hematologist Cancer Treatment Centers of America Philadelphia, PA
Monday, September 28, 2020 7:00PM – 9:00 PM ET
This virtual program is at 7:00PM Eastern, 6:00PM Central, 5:00PM Mountain, and 4:00PM Pacific.
Click here to REGISTER
Access the clinical/provider tool kit, poster portal, and additional resources @ http://oncologynurse-ce.com
PROGRAM FEATURES
Online Personalized Poster Portal
Interactive, case-based learning environment
PRESENTATION TRACKS
Immune Related Adverse Events
Immune Checkpoint Inhibitors: The Oncology Nurse’s Role in the Monitoring and Early Intervention of Immune-related Adverse Events
Arjun V. Balar, MD Associate Professor of Medicine Director, Genitourinary Medical Oncology Program Laura and Isaac Perlmutter Cancer Center NYU Langone Health New York, NY
HER2-Negative Breast Cancer
Updates for Oncology Nurses—Optimizing the Paradigm Shift Driven by CKD 4/6 Inhibitors in Metastatic HR-Positive, HER2-Negative Breast Cancer
Sramila Aithal, MD Director and Lead, Breast Center of Advanced Oncology Medical Oncologist and Hematologist Cancer Treatment Centers of America Philadelphia, PA
Comments